"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
systemic hypertension, proteinuria, iga glomerulonephritis, acute kidney injury, iga nephropathty, corona virus disease 2019, sar-cov 2 infection
Said Amin, Fawad Rahim , Mohammad Noor, Azhar Wahab, Sobia A. Qureshi
Cite this article as: Amin S, Rahim F, Noor M, et al. (June 05, 2022) COVID-19 Associated Illnesses From Alveoli to Glomeruli: A Case Report. Cureus 14(6): e25670. doi:10.7759/cureus.25670
Hypoxemic respiratory failure is the most frequent complication of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) infection. Coronavirus disease-19 (COVID-19) is no longer considered a standalone respiratory infection. It can involve other organs, including kidneys by direct invasion or indirectly through immune activation, cytokine storm, microthrombi and hemodynamic instability. Multiorgan involvement carries a worse prognosis in COVID-19.
Tubulopathy is the most frequently reported renal pathology, followed by glomerulopathies. Among the glomerulopathies, immunoglobulin A (IgA) nephropathy is less often reported. Differentiating tubulopathy from glomerulopathy is important from the management and prognostic point of view. Laboratory investigations, including urine microscopy, cannot predict glomerulopathy as a cause of renal involvement. Therefore, it is important to proceed with renal biopsy early to make a definite diagnosis.
We report a case of a 33-year-old male who presented three weeks after recovery from COVID-19 with proteinuric acute kidney injury. Subsequent renal biopsy revealed IgA nephropathy.
Involvement of the respiratory system resulting in hypoxemic respiratory failure is the commonest manifestation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection [1]. Renal involvement is seen in up to 36.6% of cases of coronavirus disease-19 (COVID-19) [2]. The mortality of COVID-19 pneumonia is higher when there is renal involvement. It has been reported that acute kidney injury (AKI) develops more frequently in ventilated patients, and one-third of them die [3].
The risk factors for AKI are older age, diabetes mellitus, cardiovascular disease, preexisting chronic kidney disease, black ethnicity, hypertension, and the need for ventilation and vasopressor medications [4]. Multiple mechanisms have been postulated for renal involvement, such as direct cytotoxicity by the viral invasion of renal parenchyma through angiotensin-converting enzyme receptors, hemodynamic instability, microthrombi, drug toxicity, and cytokine-induced injury leading to renal tubular damage [5]. Reports from China and the United States of America (USA) on renal biopsies mostly show tubulopathies and rarely immune-mediated glomerulopathies such as collapsing focal segmental glomerulonephritis (FSGS), membranous nephropathy, and anti-glomerular basement membrane disease (anti- GBM disease) [6,7]. On review of 12 postmortem kidney biopsies of COVID-19 patients, only one was reported as IgA nephropathy [8]. Nicolas et al. reported a case of Henoch Schönlein Purpura (HSP) with IgA nephropathy in a young male with no prior history except COVID-19 [7]. Suso reported HSP & IgA nephropathy in a 78-year-old male with COVID-19 [9].
We report a case of a 33-year-old male who developed proteinuria and AKI following recovery from COVID-19 infection and who was found to have IgA nephropathy on renal biopsy.
A 33-year-old man who was previously well presented with seven days history of fever, cough, and shortness of breath. He was diagnosed with a case of COVID-19 based on clinical presentation and a positive reverse transcriptase-polymerase chain reaction (RT-PCR) on a nasopharyngeal swab. He had mild SARS-CoV-2 infection as per the World Health Organization (WHO) classification for COVID-19 and received the appropriate treatment. His full blood count, C-reactive protein, urinalysis, liver, and renal function tests were unremarkable.
His symptoms improved significantly after two weeks. A week later, he developed weakness, headaches, and mild swelling of the feet. He visited the hospital again for further evaluation. His pulse was 84 beats per minute, blood pressure was 160/100 mmHg, temperature was 97F, and oxygen saturation was 96% on room air. He was having bilateral pitting pedal edema. There was no skin rash. The systemic examination was unremarkable. He was admitted for further evaluation. He had a full blood count, liver function tests, renal function tests, C-reactive protein, urinalysis, chest X-ray, electrocardiogram, and echocardiogram. Significant findings in the investigations are summarized in Table 1.
g/dL: Gram/deciliter, mcL: Microliter, mg/dL: milligram/deciliter, IU/L: International unit/liter, ELISA: Enzyme-linked immunosorbent assay, HBsAg: Hepatitis B surface antigen, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, PCR: Polymerase chain reaction
Considering his symptoms, proteinuria and raised creatinine, an ultrasound abdomen and pelvis, a urine albumin creatinine ratio, anti-nuclear antibodies, anti-double-stranded deoxyribonucleic acid antibodies, serum C3 and C4 levels, anti-glomerular basement membrane antibodies, cytoplasmic-antineutrophilic cytoplasmic antibodies, and perinuclear-antineutrophilic cytoplasmic antibodies were advised. The results are summarized in Table 2.
ACR: albumin creatinine ratio, ANA: antinuclear antibodies, Anti-dsDNA: anti-double stranded deoxyribonucleic acid antibodies, Anti-GBM: Anti-glomerular membrane antibodies, c-ANCA: Cytoplasmic-antineutrophilic cytoplasmic antibodies, p-ANCA: Perinuclear-antineutrophilic cytoplasmic antibodies
Given the raised creatinine, proteinuria, and echogenic kidneys, he underwent an ultrasound-guided percutaneous renal biopsy. Pending the result of the renal biopsy, he was started on furosemide 40 mg daily and enalapril 10 mg daily. His edema disappeared, and his blood pressure remained 120/70 mmHg. The renal biopsy was reported five days after the procedure. It showed a total of eight glomeruli showing focal and segmental proliferation and inflammatory cells in the interstitium. The immunofluorescence revealed deposition of IgA in the glomeruli and renal tubules consistent with IgA nephropathy (Figures 1-4).
A multidisciplinary team, including a nephrologist, decided to continue the same treatment and to review him in four weeks. He was discharged from the hospital with the advice to restrict salt and regularly check blood pressure at home. He was reviewed in the outpatient department three weeks later. His blood pressure was 120/75 mmHg, pulse was 78 beats per minute, the temperature was 98F, and oxygen saturation was 98% on room air. There was no edema, and systemic examination was unremarkable. His serum creatinine was 1.2 mg/dl, urea was 36 mg/dl, and urinalysis showed trace protein. It was decided to withhold furosemide and continue enalapril. He is booked for the next outpatient visit in two months. He was advised to report early if he notices edema or worsening blood pressure.
The world’s healthcare paradigm has changed in a brief period of the pandemic of COVID-19. The notion that COVID-19 is a lung disease has changed soon with the discovery of the relationship between the ACE receptors and SARS-CoV-2 and the reports of other organ involvement worldwide.
The widespread presence of the ACE-2 receptors all over the body, which act as the primary entry point for the virus, provides the basis for the multi-system involvement in COVID-19 [10]. Kidneys are the new organs of interest for COVID-19 because of the widespread expression of ACE-2 receptors. Though hematuria, proteinuria, and deranged renal functions are the most common clinical presentations of renal involvement, the underlying pathophysiologic mechanism is multifactorial. Understanding the pathophysiologic mechanism of renal insult in COVID-19 is not straightforward. Though ACE receptors are expressed in renal tissue, there is controversy regarding direct toxicity by SARS-CoV-2. Other mechanisms postulated for AKI in COVID-19 include hemodynamic instability, drug toxicity, microthrombi in the renal vasculature, and cytokine-induced damage as part of the cytokine storm [11]. The SARS-CoV-2 induced cascade of events has been hypothesized to include circulating galactose deficient IgA1 (gd-IgA1) antibodies, formation of autoreactive antibodies to gd-IgA1, early conversion to IgA response, hyperactivation of IgA response in COVID-19 patients and development of immune complexes that deposit in various tissues such as skin, soft tissues, and kidneys [12].
Despite an initial hesitancy to perform autopsies due to fear of aerosolization of viral particles, many studies on postmortem biopsies published since May 2020 have highlighted different pathophysiologic, histologic, and immune-mediated patterns of COVID-19 related nephropathies [13].
Su H et al. from China reported the autopsy data of 26 cases. Almost all cases had acute tubular injury - loss of brush border, vacuolar degeneration and dilatation of tubular lumen with cellular debris, and nonspecific immunoglobulin M (IgM) and C3 trapping in glomeruli on immunofluorescence with corona-like particles on electron microscopy [14].
Tubulopathies were the most frequent histologic pattern in 46 postmortem biopsy reports stated by Dominick Santoriello et al. from New York, USA [8]. Sharma et al. from New York have also observed a few cases of immune-mediated glomerulopathies and thrombotic microangiopathies [15]. Larsen et al. from the USA presented a case report of Collapsing Glomerulopathy in a patient with COVID-19 [16].
We report an atypical and exceptional case of IgA nephropathy due to COVID-19. IgA-related vasculitis and IgA nephropathy are rarely reported to be associated with COVID-19 infection. Only 13 cases of IgA vasculitis with COVID-19 and four cases after COVID-19 vaccination have been documented so far [17]. Our case report is on a young male of 33 years who developed IgA nephropathy three weeks after COVID-19. These findings are consistent with the literature review, which shows a male predominance and the development of IgA nephropathy within 14 to 40 days of COVID-19 [18]. This case will add to the data about COVID-19-induced glomerulopathies, especially in developing countries like Pakistan. We acknowledge that electron microscopy was not performed on the specimens as this facility was not available locally.
Although respiratory system involvement is the most frequent presentation of SARS-CoV-2 infection, concurrent renal involvement is not uncommon and is associated with poor prognosis. Renal involvement can happen at the time of COVID-19 symptoms and may develop several weeks after recovery from COVID-19. IgA nephropathy has been infrequently reported in association with COVID-19. The attending physician should be vigilant for renal involvement, and an early renal biopsy should be performed to make a definite diagnosis.
Internal Medicine, Khyber Girls Medical College, Peshawar, PAK
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
Internal Medicine, Khyber Girls Medical College, Peshawar, PAK
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
Internal Medicine, Khyber Girls Medical College, Peshawar, PAK
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK
Human subjects: Consent was obtained or waived by all participants in this study. Khyber Girls Medical College, Peshawar, Pakistan issued approval 6237/Estt./KGMC. dated 08.04.2022. The case is reported after approval by the institutional review board of Khyber Girls Medical College, Peshawar, Pakistan. . Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
We acknowledge the help and support of Dr. Shagufta Nasir Parvez (histopathologist), Mr. Abid Khan (Senior technician) and Mr. Sajawal Khan (senior laboratory assistant). We also acknowledge the help and support of Dr. Muhammad Irfan in proof reading the manuscript.
Amin S, Rahim F, Noor M, et al. (June 05, 2022) COVID-19 Associated Illnesses From Alveoli to Glomeruli: A Case Report. Cureus 14(6): e25670. doi:10.7759/cureus.25670
Peer review began: May 30, 2022 Peer review concluded: June 03, 2022 Published: June 05, 2022
© Copyright 2022 Amin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
g/dL: Gram/deciliter, mcL: Microliter, mg/dL: milligram/deciliter, IU/L: International unit/liter, ELISA: Enzyme-linked immunosorbent assay, HBsAg: Hepatitis B surface antigen, HCV: Hepatitis C virus, HIV: Human immunodeficiency virus, SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2, PCR: Polymerase chain reaction
ACR: albumin creatinine ratio, ANA: antinuclear antibodies, Anti-dsDNA: anti-double stranded deoxyribonucleic acid antibodies, Anti-GBM: Anti-glomerular membrane antibodies, c-ANCA: Cytoplasmic-antineutrophilic cytoplasmic antibodies, p-ANCA: Perinuclear-antineutrophilic cytoplasmic antibodies
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.
This link will take you to a third party website that is not affiliated with Cureus, Inc. Please note that Cureus is not responsible for any content or activities contained within our partner or affiliate websites.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.
Visit our SIQ™ page to find out more.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
Already have an account? Sign in.
Please note that by doing so you agree to be added to our monthly email newsletter distribution list.
By joining Cureus, you agree to our Privacy Policy and Terms of Use.